Takeda Pharmaceutical Company Limited (TAK) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Tokyo, Japan. The current CEO is Christophe Weber.
TAK has IPO date of 2010-01-05, 49,281 full-time employees, listed on the NYSE, a market capitalization of $56.39B.
Takeda Pharmaceutical Company Limited is a globally diversified pharmaceutical company headquartered in Tokyo, Japan, with operations across North America, Europe, Latin America, Russia, and Asia. Founded in 1781, Takeda engages in the research, development, manufacturing, and commercialization of pharmaceutical products across key therapeutic areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company markets numerous branded products such as Entyvio, Velcade, Adcetris, and Trintellix, and maintains an extensive portfolio of strategic collaborations and licensing agreements with leading biotech firms and research institutions to support its pipeline development and innovation initiatives.
